



IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q94052

Keuk Chan BANG, et al.

Appln. No.: 10/574,098

Group Art Unit: Unknown

Confirmation No.: Unknown

Examiner: Unknown

Filed: March 31, 2006

For: P-GLYCOPROTEIN INHIBITOR, METHOD FOR PREPARING THE SAME AND
PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. Korean Patent Application No. 10-2005-34024 A, published April 14, 2005 with Abstract (corresponds to Korean Patent No. 10-0580743, published May 9, 2006).
2. WO 94/01408, published January 20, 1994.
3. WO 98/17648, published April 30, 1998.
4. WO 03/095447, published November 20, 2003.
5. M. Roe et al., "Reversal of P-Glycoprotein Media Multidrug Resistance by Novel Anthranilamide Derivatives", Bioorganic & Medicinal Chemistry Letters 9, (4), 1999, pp. 595-600.
6. P. Mistry et al., "In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576", Cancer Research, 61 (2), January 15, 2001.

Keuk Chan BANG et al.
U.S. Appln. No.: 10/574,098
INFORMATION DISCLOSURE STATEMENT

7. A. Stewart et al., "Phase I Trial of XR9576 in Healthy Volunteers Demonstrates Modulation of P-Glycoprotein in CD56⁺ Lymphocytes after Oral and Intravenous Administration", Clinical Cancer Research, Vol. 6, November 2000, pp. 4186-4191.

One copy of each of the listed documents is submitted herewith

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Sunhee Lee
Registration No. 53,892

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: July 14, 2006



Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/574,098
Confirmation Number	Unknown
Filing Date	March 31, 2006
First Named Inventor	Keuk Chan BANG
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q94052

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		KR	10-580743	B1	05/09/2006	Hanmi Pharm. Co., Ltd.	Abstract
		WO	94/01408	A1	01/20/1994	Laboratoires Glaxo	
		WO	98/17648	A1	04/30/1998	Xenova Limited	
		WO	03/095447	A1	11/20/2003	Xenova Limited	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		M. Roe et al., "Reversal of P-Glycoprotein Media Multidrug Resistance by Novel Anthranilamide Derivatives", Bioorganic & Medicinal Chemistry Letters 9, (4), 1999, pp. 595-600.	
		P. Mistry et al., "In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576", Cancer Research, 61 (2), January 15, 2001.	
		A. Stewart et al., "Phase I Trial of XR9576 in Healthy Volunteers Demonstrates Modulation of P-Glycoprotein in CD56 ⁺ Lymphocytes after Oral and Intravenous Administration", Clinical Cancer Research, Vol. 6, November 2000, pp. 4186-4191.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.